Next-Generation Dual Checkpoint Nanobody Targeting PDCD1 and TIGIT for Advanced Cancer Immunotherapy

VHH-P482 is a fully humanized nanobody-based bispecific antibody that targets both programmed cell death 1 (PDCD1) and T cell immunoreceptor with Ig and ITIM domains (TIGIT). Currently in the Biological Testing development stage, VHH-P482 is designed to enhance anti-tumor immunity for cancer therapy by simultaneously blocking these two critical immune checkpoints. By combining the specificity of an affinity-matured anti-PD1 antibody with a humanized anti-TIGIT nanobody on an IgG1 scaffold, this innovative molecule offers a promising approach for overcoming tumor immune evasion. VHH-P482 is positioned to address significant unmet needs in the cancer immunotherapy landscape.

Licensing Opportunity

VHH-P482 is currently available for out-licensing and collaborative development opportunities. We welcome inquiries from partners interested in advancing this leading-edge bispecific nanobody program for cancer immunotherapy.

Development Phase

Modality

VHH-P482 utilizes a novel bispecific IgG1 antibody format that integrates an affinity-matured anti-PD1 variable and constant region with a humanized anti-TIGIT nanobody. The nanobody, characterized by its small size and high stability, is engineered for superior tumor penetration and reduced immunogenicity. Both binding domains are fused to a human IgG1 Fc, enhancing effector functionality and serum half-life, while a flexible linker ensures optimal orientation and accessibility for target engagement. This structural innovation provides dual checkpoint blockade within a single molecule, potentially leading to synergistic immune activation against cancer cells, and offers manufacture and delivery advantages over conventional monoclonal antibodies.

Target

PDCD1 and TIGIT are critical immunoregulatory receptors belonging to distinct families of immune checkpoint proteins. PDCD1, primarily expressed on activated T cells, regulates peripheral tolerance and prevents autoimmunity by inhibiting T cell receptor signaling. TIGIT, found on T cells and natural killer (NK) cells, dampens immune responses in the tumor microenvironment. Both PDCD1 and TIGIT have been validated as promising targets in cancer, as tumor cells exploit these pathways to evade immune surveillance. Therapeutic blockade of PDCD1 and TIGIT can restore anti-tumor immunity, enabling robust T cell activity. Targeting both PDCD1 and TIGIT with VHH-P482 represents a strategic approach to counteract immune suppression, maximizing therapeutic potential and offering a differentiated value proposition for cancer immunotherapy development.

Mechanism of Action

VHH-P482 acts as a dual immune checkpoint inhibitor by specifically binding to PDCD1 and TIGIT on effector lymphocytes. Through high-affinity interaction with these checkpoints, the molecule prevents the engagement of their respective ligands, reversing inhibitory signals that restrain cytotoxic T cell and NK cell activity. This dual blockade reinvigorates anti-tumor immune responses within the tumor microenvironment. The nanobody-based engineering of VHH-P482 not only enables efficient bispecificity but also offers the flexibility for further therapeutic development, such as antibody-drug conjugates (ADCs) or novel multispecific formats. The modulation of both PDCD1 and TIGIT checkpoints may provide synergistic and durable clinical benefits in cancer therapy.

Cancer

Cancer remains a leading cause of death worldwide, accounting for a significant proportion of global morbidity and mortality. Characterized by the uncontrolled growth of abnormal cells, cancer can affect virtually any tissue or organ. Major therapeutic strategies include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted small molecules. While these modalities have improved patient outcomes, many cancers continue to exhibit therapy resistance, high recurrence rates, and immune escape mechanisms. Immunotherapy, particularly immune checkpoint inhibition, has revolutionized cancer care by unleashing the body's immune system against tumors. However, not all patients respond, and the development of resistance through alternative immune evasion pathways poses ongoing challenges. VHH-P482, by targeting both the PDCD1 and TIGIT axes, is well-positioned to address these unmet needs by offering a more robust, multi-faceted approach to tumor immune activation. This innovative therapeutic strategy has the potential to benefit a diverse patient population across various tumor types and advance the state of cancer immunotherapy.